Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.’s QURE AMT-130 for Huntington’s disease on Thursday

This designation is in addition to the Regenerative Medicine Advanced Therapy (RMAT) designation, the Orphan Drug designation and the Fast Track designation, all of which were previously granted by the FDA to AMT-130.

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms, including chorea, behavioral abnormalities and cognitive decline, resulting in progressive physical and mental deterioration.

Also Read: uniQure/ CSL Behring’s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

According to a 2021 study in Neuroepidemiology, approximately 70,000 people have been diagnosed with Huntington’s disease in the U.S. and Europe.

The Breakthrough Therapy designation is supported by clinical data from the ongoing Phase 1/2 trials of AMT-130 for Huntington’s disease.

In July 2024, uniQure presented interim data at 24 months, showing dose-dependent slowing of disease progression based on the cUHDRS in treated patients compared to a propensity-weighted natural history. To date, 45 patients have received AMT-130.

The Breakthrough Therapy designation is intended to expedite the development and review of investigational therapeutic candidates for treating a serious condition. Preliminary clinical evidence suggests that the drug may show substantial improvement over available therapy on one or more clinically significant endpoints.

In general, the preliminary clinical evidence should show a clear advantage over available therapy. A drug with Breakthrough Therapy designation is eligible for all Fast Track designation features and intensive guidance on an efficient drug development program.

uniQure Stock Predication For 2025

Equity research analysts, both on and off Wall Street, typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.

Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at uniQure, an investor could make an assessment of a stock's long-term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many consider a bullish signal, they can extrapolate that trend into the future using a trendline. For uniQure, the 200-day moving average sits at $9.61, according to Benzinga Pro, which is above the current price of $9.39. For more on charts and trend lines, see a description here.

Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors can use trend lines to make an educated guess about where a stock might trade in the future if conditions remain stable.

Price Action: QURE stock is up 49.8% at $14.07 during the premarket session at the last check on Thursday.

Read Next:

• Interactive Brokers Misses Q1 Earnings: Analyst Flags Weaker Securities Lending Revenue

Photo: Shutterstock